You are viewing: Italy Gene Editing Market analysis
Part of: Gene Editing Market (Global)

The Italy Gene Editing Market was valued at $32.2 Million in 2024 and projected to reach to $53.4 Million by 2029, representing a compound annual growth rate of 10.6%. Italy's gene editing market is poised for sustained expansion driven by increasing healthcare expenditure, growing prevalence of genetic disorders, and strengthened government support for biotechnology research.

Italy Gene Editing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Italy Gene Editing Market Trends and Insights

  • This 10.6% compound annual growth rate reflects Italy's increasing investment in advanced biotechnology and precision medicine initiatives.
  • Italy's healthcare sector is leveraging gene editing technologies to address genetic disorders and develop innovative therapeutic solutions, positioning the country as a key player in Europe's gene editing landscape. The Italian market benefits from strong research institutions, government support for life sciences innovation, and growing collaboration between academic centers and pharmaceutical companies.
  • Italy's regulatory framework continues to evolve to accommodate emerging gene editing therapies, while healthcare providers increasingly adopt CRISPR and other gene-editing platforms.
  • By 2029, Italy is expected to capture significant market share within the European gene editing sector, driven by clinical applications and rising demand for personalized medicine solutions..

Key Market Statistics

  • CAGR (2024-2029) 10.6% CAGR
  • Market Size, 2024 ~USD 32.2 Million
  • Forecast, 2029 ~USD 53.4 Million
  • Country Italy

Italy Gene Editing Market Overview

Market Valuation Growth :

Italy's gene editing market is valued at $32.2 million in 2024, with projections reaching $53.4 million by 2029, representing a robust 10.6% CAGR that outpaces the global average of 10.2%.

Biotechnology Investment Surge :

Italy is significantly increasing investment in advanced biotechnology infrastructure and precision medicine initiatives, positioning itself as a key player in European gene editing innovation and research development.

Genetic Disorder Treatment Focus :

Italian healthcare providers are actively adopting gene editing technologies to address genetic disorders and develop innovative therapeutic solutions, driving clinical adoption across major medical centers.

European Regulatory Alignment :

Italy's gene editing market benefits from harmonized EU regulatory frameworks and growing collaboration with European research institutions, facilitating faster market entry and clinical trial acceleration.

Italy Gene Editing Market Dynamics

  • The country's robust pharmaceutical sector and academic research institutions are catalyzing innovation in CRISPR and alternative gene editing platforms.
  • Italy's alignment with EU regulatory standards and participation in pan-European research initiatives will accelerate market penetration and clinical applications through 2029. The Italian healthcare system's emphasis on precision medicine and personalized treatment approaches creates significant opportunities for gene editing adoption.
  • Strategic partnerships between Italian biotech firms, hospitals, and research centers are expected to drive commercialization of novel therapies.
  • Investment in manufacturing capabilities and skilled workforce development will further strengthen Italy's competitive position in the European gene editing landscape..

Market Ecosystem

logo-mobile

GENE EDITING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Collaborates with Beam Therapeutics to develop in vivo base editing therapies targeting rare genetic diseases affecting the liver, muscles, and central nervous system. The programs utilize precision genome editing and lipid nanoparticle-based delivery technologies. Supports the development of targeted genetic medicines, enables precise modification of disease-associated DNA sequences, and advances research into potential treatments for inherited disorders.
company logo
Supports genome editing research through its Somatic Cell Genome Editing (SCGE) program, focusing on CRISPR-based technologies, targeted delivery systems, genome editing efficiency, and safety evaluation for therapeutic applications. Accelerates the development of genome editing tools, improves editing specificity and delivery efficiency, supports off-target analysis, and advances research into potential gene editing therapies for genetic diseases.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Key Takeaways

  • Italy's gene editing market is valued at $32.2 million in 2024 and will reach $53.4 million by 2029, representing a 10.6% CAGR.
  • Italy's robust research infrastructure and government support are driving adoption of advanced gene-editing technologies across healthcare institutions.
  • Italy's regulatory environment is adapting to facilitate clinical deployment of gene editing therapies for genetic disorders.
  • Italy is positioned as a significant European hub for gene editing innovation, with growing investment in precision medicine and personalized therapeutics.

Gene Editing Market Report Scope

Report Metric Details
Base Year 2024
Fastest Growing Segment CROS & CDMOS (End User)
Forecast Period 2024–2029
Growth Rate CAGR of 10.2% from 2024 to 2029
Largest Segment PRODUCTS (Offering)
Market Size Base Year (Billions) ~USD 4.67 (2024)
Revenue Forecast (Billions) ~USD 7.59 (2029)
Segments Covered Offering, Type, Technique, Technology, Application, End User

Italy Gene Editing Market Report Segmentation

6 segment dimensions are covered across the global market.

By Offering

  • Products
  • Services

By Type

  • Cell Line Development & Engineering
  • Gene Editing Kits
  • Gene Editing Libraries
  • Gene Editing Reagents
  • Grna Synthesis & Vector Construction
  • Library Construction & Screening
  • Other Services
  • Reagents & Consumables
  • Software & Systems

By Technique

  • Gene Silencing
  • Knock-In
  • Knock-Out
  • Other Techniques

By Technology

  • Antisense
  • Base Editing
  • Crispr
  • Other Technologies
  • Rnai
  • Talens
  • Zfns

By Application

  • Cell Line Engineering
  • Drug Discovery & Development
  • Genome Editing
  • Other Applications

By End User

  • Academic & Research Institutes
  • Cros & Cdmos
  • Other End Users
  • Pharmaceutical & Biotechnology Companies

ITALY: GENE EDITING PRODUCTS MARKET, BY END USER, 2022–2029

Segment20222023202420252026202720282029CAGR (%)
ACADEMIC & RESEARCH INSTITUTES21.820.721.323.325.527.930.633.59.5
CROS & CDMOS10.19.710.211.312.61415.517.311.1
OTHER END USERS10.19.39.29.710.210.811.4125.4
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES30.828.929.531.934.637.540.644.28.4
TOTAL72.868.770.276.382.990.298.1106.98.8

ITALY: GENE EDITING SERVICES MARKET, BY END USER, 2022–2029

Segment20222023202420252026202720282029CAGR (%)
ACADEMIC & RESEARCH INSTITUTES9.48.99.810.912.213.615.217.111.7
CROS & CDMOS21.92.22.633.544.615.8
OTHER END USERS5.75.25.666.577.68.28.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES14.413.514.716.21819.92224.410.6
TOTAL31.429.632.335.839.74448.854.310.9

Target Audience

  • Biotech & Pharmaceutical Companies : Italian and international biotech firms need market-specific data to develop go-to-market strategies, assess competitive positioning, and identify clinical partnership opportunities in Italy's growing gene editing sector.
  • Healthcare Investors & VCs : Investment firms require detailed Italy market intelligence to evaluate funding opportunities, assess portfolio company growth potential, and identify emerging biotech startups with strong Italian market presence.
  • Hospital & Clinical Networks : Italian healthcare institutions need market insights to guide technology adoption decisions, budget allocation for gene editing capabilities, and strategic planning for precision medicine programs.
  • Government & Policy Makers : Italian health authorities and policymakers require market data to inform healthcare policy, research funding priorities, and regulatory frameworks supporting gene editing innovation and patient access.
  • Research Institutions & Academia : Italian universities and research centers need market intelligence to align research initiatives with commercial opportunities, secure funding, and collaborate with industry partners in gene editing development.

Key Companies in the Italy Gene Editing Market

CompanyHQOwnershipStrongest segments
EPPENDORF AGGermanyPrivate CompanyLiquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
ILLUMINA INCUnited StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
CALYXTUnited StatesPublic CompanyRTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects,
MAXCYTE, INCUnited StatesPublic CompanyExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables,
BECKMAN COULTERUnited StatesPrivate CompanyClinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments,
TAKEDA PHARMACEUTICAL COMPANYJapanPublic CompanyGastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone),
DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables),
REVVITY, INC.United StatesPublic CompanyDiagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms,
THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
LONZASwitzerlandPublic CompanyIntegrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
SANGAMO THERAPEUTICSUnited StatesPublic CompanyHemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant),
PRECISION BIOSCIENCESUnited StatesPublic CompanyARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243),
CELLECTIS S.A.FrancePublic CompanyAllogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue,
REGENERON PHARMACEUTICALS, INC.United StatesPublic CompanyEYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics),
TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related),

EPPENDORF AG

Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.

ILLUMINA INC

Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.

CALYXT

Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.

MAXCYTE, INC

MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.

BECKMAN COULTER

Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.

TAKEDA PHARMACEUTICAL COMPANY

Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.

DANAHER CORPORATION

Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.

REVVITY, INC.

Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

MERCK KGAA

Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.

GENSCRIPT

GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.

LONZA

Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.

SANGAMO THERAPEUTICS

Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.

PRECISION BIOSCIENCES

Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.

CELLECTIS S.A.

Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.

REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.

TAKARA BIO INC.

Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.

Reasons to Buy this Report

  • Italy-Specific Market Sizing : Access precise valuation data for Italy's gene editing market with detailed 2024-2029 forecasts, enabling accurate investment planning and resource allocation decisions specific to the Italian healthcare landscape.
  • Competitive Landscape Analysis : Understand Italy's unique competitive dynamics, key market players, and emerging biotech companies operating in the Italian gene editing space to identify partnership and acquisition opportunities.
  • Regulatory & Reimbursement Insights : Gain comprehensive understanding of Italian healthcare regulations, EU compliance requirements, and reimbursement pathways specific to gene editing therapies for informed market entry strategies.
  • Clinical Adoption Trends : Identify which genetic disorders are prioritized in Italian clinical settings, hospital adoption rates, and physician preferences to tailor product development and commercialization strategies effectively.
  • Investment & Growth Opportunities : Discover high-potential segments within Italy's gene editing market, funding trends, and strategic growth areas to optimize investment decisions and identify emerging market gaps.

Frequently asked questions

What is the current size of Italy's gene editing market?

Italy's gene editing market was valued at $32.2 million in 2024 and is projected to grow to $53.4 million by 2029.

What is the expected growth rate for Italy's gene editing market?

Italy's gene editing market is expected to grow at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2029.

Which gene editing technologies are most prevalent in Italy?

CRISPR-Cas9 and other advanced gene-editing platforms are increasingly adopted across Italy's research institutions and healthcare providers for therapeutic applications.

What factors are driving growth in Italy's gene editing market?

Italy's market growth is driven by strong research institutions, government support for biotechnology innovation, regulatory framework evolution, and rising demand for personalized medicine solutions.

How does Italy's gene editing market compare to other European countries?

Italy is emerging as a significant European hub for gene editing innovation, with competitive growth rates and substantial investment in precision medicine and therapeutic development.

RESEARCH METHODOLOGY

This study involved four major activities in estimating the current size of the gene editing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used primarily to identify and gather information for this extensive, technical, market-oriented, and commercial study. The secondary sources referred to for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global gene editing market, and the findings were validated through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Gene Editing Market 
 Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global gene editing market size was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

Gene Editing Market Top Down and Bottom Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

Market Definition

Gene editing refers to technologies used to modify, insert, delete, or regulate specific DNA sequences in cells and organisms. These technologies enable targeted genetic modifications through approaches such as CRISPR-Cas, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), base editing, and other genome engineering techniques. The gene editing market includes products such as reagents & consumables and software & systems, as well as specialized services such as cell line development & characterization, gRNA synthesis & vector construction, and library construction & screening. These products and services are widely used in cell line engineering, genome editing, drug discovery and development, and genetic research. They also support applications in biotechnology, biopharmaceutical production, and therapeutic development. Rising investment in genetic research, advances in genome-editing technologies, and the growing adoption of precision medicine are driving demand for gene editing products and services across pharmaceutical, biotechnology, and academic research institutions.

Key Stakeholders

  • Academic Research Institutes
  • Raw Materials Manufacturers & Distributors
  • Contract Research Organizations (CROs)
  • Service Providers
  • Market Research and Consulting Firms
  • Pharmaceutical & Biotechnology Companies
  • Regulatory Agencies
  • Venture Capitalists
  • Government Organizations
  • Private Research Firms
  • Contract Development and Manufacturing Organizations (CDMOs)

Report Objectives

  • To define, describe, and forecast the gene editing market by product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall gene editing market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil and the Rest of Latin America), the Middle East (GCC Countries and the Rest of the Middle East), and Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available customizations:

Based on the market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the market in the Rest of Europe, by country
  • Further breakdown of the market in the Rest of Asia Pacific, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Cross-segment analysis

 

Get the Full Gene Editing Market Report

Full forecast, segment splits, and company analysis for all Gene Editing Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status